Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Boehringer, Vanderbilt pact targets KRAS

by Rick Mullin
March 13, 2017 | A version of this story appeared in Volume 95, Issue 11

[+]Enlarge
Credit: Vanderbilt
A researcher in the Fesik lab at Vanderbilt.
A photo of a researcher in the Fesik lab at Vanderbilt.
Credit: Vanderbilt
A researcher in the Fesik lab at Vanderbilt.

Advancing a two-year-old cancer drug discovery partnership, Boehringer Ingelheim and Vanderbilt University will research and develop small molecules targeting a protein called SOS that acts as a molecular switch activating KRAS, a gene essential to normal tissue signaling. Mutations of the gene are responsible for the onset of various forms of cancer. The venture is based on research done in the laboratory of Vanderbilt chemist Stephen W. Fesik. The partners previously identified compounds that bind to KRAS with high affinity.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.